Glenmark gets USFDA’s nod for Arformoterol Tartrate Inhalation Solution

23 Jun 2021 Evaluate

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials, the generic version of BROVANA Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc. Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina, and marks the company’s first nebulizer approval.

According to IQVIA sales data for the 12 month period ending April 2021, the BROVANA Inhalation Solution, 15 mcg/2 mL market achieved annual sales of around $437.9 million. Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma Share Price

2009.00 -9.25 (-0.46%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×